Fusen Pharmaceutical (1652) Announces Selection in Eleventh Batch of National Centralised Medicines Procurement
Bulletin Express
Oct 30
Fusen Pharmaceutical Company Limited (Stock Code: 1652) announced on 30 October 2025 that one of its products, Metformin Empagliflozin Tablets (I) (metformin hydrochloride 500 mg and empagliflozin 5 mg), was successfully selected in the tender results of the eleventh batch of the National Centralised Medicines Procurement in China on 27 October 2025.
The announcement indicates that the update is made on a voluntary basis to inform shareholders and potential investors of recent business developments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.